Among brain tumors, glioblastoma multiforme (GBM) is the most prevalent and potentially fatal kind. The location of the tumor, its heterogeneity, the presence of the blood-brain barrier (BBB), and other factors all contribute to the difficulty of treating GBM, and tumor recurrence is common even after treatment with surgery and chemotherapy. L/R-T/V-NLCs were shown to have a high efficiency in encapsulating drugs and a high stability at the nanoscale. While SLNs and NLCs serve a significant role as drug carriers in GBM treatment, we explore the key challenges in treating GBM in this study, and the full range of modification techniques that try to alter the SLN and NLC composition for the betterment of treatment results.

Gliomatosis cerebri, nanostructured lipid carriers, lactoferrin, arginine–glycine–aspartic acid peptide, vincristine, temozolomide